Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average PT from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.00.

Several research analysts have recently commented on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Monday, May 19th.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS traded down $0.05 during midday trading on Monday, reaching $1.14. 485,185 shares of the company traded hands, compared to its average volume of 742,626. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.39. The stock's 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.30. The firm has a market cap of $70.62 million, a PE ratio of -0.72 and a beta of 1.18.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). On average, equities research analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC boosted its position in Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after buying an additional 1,043,228 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Pyxis Oncology by 36.6% during the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock valued at $106,000 after acquiring an additional 18,128 shares during the period. ProShare Advisors LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter valued at $26,000. Ameriprise Financial Inc. bought a new position in Pyxis Oncology in the fourth quarter valued at about $35,000. Finally, American Century Companies Inc. increased its position in Pyxis Oncology by 88.1% in the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock worth $468,000 after purchasing an additional 140,498 shares during the period. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.